MIRA Pharmaceuticals shares are trading higher after company announced it achieved 100% reversal of neuropathic pain with oral Ketamin-2 in a rat study.
Portfolio Pulse from Benzinga Newsdesk
MIRA Pharmaceuticals shares rise as the company reports a 100% reversal of neuropathic pain in a rat study using oral Ketamin-2.
August 23, 2024 | 8:20 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
MIRA Pharmaceuticals' stock is trading higher following the announcement of a successful rat study showing 100% reversal of neuropathic pain using oral Ketamin-2.
The announcement of a 100% reversal of neuropathic pain in a rat study is a significant positive development for MIRA Pharmaceuticals, likely boosting investor confidence and driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100